Participants' descriptions of social support within a multisite intervention for HIV-seropositive injection drug users (INSPIRE)

Journal of Acquired Immune Deficiency Syndromes

Volumn 46, Issue SUPPL. 2, 2007, Pages

  Mitchell, Shannon Gwin ^a,g   Edwards, Lorece V ^a   Mackenzie, Sonja ^b   Knowlton, Amy R ^a   Valverde, Eduardo E ^c   Arnsten, Julia H ^d   Santibanez, Scott ^e   Latka, Mary H ^f   Mizuno, Yuko ^e  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f NEW YORK ACADEMY OF MEDICINE   (United States)

^g Friends Social Research Center   (United States)

Author keywords

HIV; IDU; Process evaluation; Qualitative; Risk reduction; Social support

Indexed keywords

ADULT; ARTICLE; DRUG USE; FEMALE; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SELF EVALUATION; SEXUAL BEHAVIOR; SOCIAL SUPPORT;

BEHAVIOR CONTROL; DATA COLLECTION; FEMALE; HIV INFECTIONS; HUMANS; MALE; RISK FACTORS; SELF DISCLOSURE; SOCIAL SUPPORT; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES;

EID: 37349100863     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181576808     Document Type: Article

References (33)

1. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2003, vol. 16. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention; 2005:32. Available at: http://www.cdc.gov/hiv/stats/hasrlink.htm. Accessed May 15, 2006.
2. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA. 1998;280:1497-1503.
3. Gifford AL, Groessl EJ. Chronic disease self-management and adherence to HIV medications. J Acquir Immune Defic Syndr. 2002;31(Suppl): S163-S166.
4. Palella FJ, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
5. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377-391.
6. Chan AC, Palepu A, Guh DP, et al. HIV-positive injection drug users who leave the hospital against medical advice. J Acquir Immune Defic Syndr. 2004;1:56-59.
7. Knowlton AR, Arnsten J, Eldred L, et al. Individual, interpersonal, and structural correlates of effective HAARTuse among urban active injection drug users. J Acquir Immune Defic Syndr. 2006;4:486-491.
8. Lucas GM, Cheever LW, Chaisson RE, et al. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27:251-259.
9. Lucas GM, Gebo KA, Chaisson RE, et al. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16:767-774.
10. Knowlton AR, Latkin CA, Schroeder JR, et al. Longitudinal predictors of depressive symptoms among low income injection drug users. AIDS Care. 2001;13:549-559.
11. House JS, Umberson D, Landis KR. Structures and processes of social support. Annu Rev Sociol. 1988;14:293-318.
12. DiMatteo MR. Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol. 2004;23:207-218.
13. Latkin CA, Knowlton AR. Micro-social structural approaches to HIV prevention: a social ecological perspective. AIDS Care. 2005;17(Suppl): S102-S113.
14. Margolin A, Avants S, Warburton LA, et al. A randomized clinical trial of a manual-guided risk reduction intervention for HIV-positive injection drug users. Health Psychol. 2003;22:223-228.
15. Strathdee SA, Ricketts EP, Huettner S, et al. Facilitating entry into drug treatment among injection drug users referred from a needle exchange program: Results from a community-based behavioral intervention trial. Drug Alcohol Depend. 2006;83:225-232.
16. Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2002;31(Suppl):S123-S127.
17. Ashton E, Vosvick M, Chesney M, et al. Social support and maladaptive coping as predictors of the change in physical health symptoms among persons living with HIV/AIDS. AIDS Patient Care STDS. 2005;19:587-598.
18. Brashers DE, Neidig JL, Goldsmith DJ. Social support and the management of uncertainty for people living with HIV or AIDS. Health Commun. 2004;16:305-331.
19. Farber EW, Mirsalimi H, Williams KA, et al. Meaning of illness and psychological adjustment to HIV/AIDS. Psychosomatics. 2003;44:485-491.
20. Fleishman JA, Sherbourne CD, Crystal S, et al. Coping, conflictual social interactions, social support, and mood among HIV-infected persons. Am J Community Psychol. 2000;28:421-453.
21. Glass TR, De Geest S, Weber R, et al. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients. J Acquir Immune Defic Syndr. 2006;41:385-392.
22. Prado G, Feaster DJ, Schwartz SJ, et al. Religious involvement, coping, social support, and psychological distress in HIV-seropositive African American mothers. AIDS Behav. 2004;8:221-235.
23. Stewart KE, Cianfrini LR, Walker JF. Stress, social support and housing are related to health status among HIV-positive persons in the Deep South of the United States. AIDS Care. 2005;17:350-358.
24. Cormier M. The role of hepatitis C support groups. Gastroenterol Nurs. 2005;28(Suppl):S4-S9.
25. Purcell DW, Metsch LR, Latka M, et al. Interventions for seropositive injectors - research and evaluation: an integrated behavioral intervention with HIV-positive injection drug users to address medical care, adherence, and risk reduction. J Acquir Immune Defic Syndr. 2004;37(Suppl):S110-S118.
26. Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991;32:705-714.
27. Jones, TS, Anderson, T. "Addictphobia" a new concept to capture the social stigma against drug users and limitations on HIV prevention for drug users [abstract 316]. Presented at: National HIV Prevention Conference; Atlanta, GA. 1999.
28. Purcell DW, Latka MH, Metsch LR, et al. Results from a randomized trial of a peer-mentoring intervention to reduce HIV transmission and increase access to care and adherence to HIV medications among HIV-seropositive injection drug users. J Acquir Immune Defic Syndr. 2007;46(Suppl 2): S35-S47.
29. Crepaz N, Hart TA, Marka G. Highly active antiretroviral therapy and sexual risk behavior. JAMA. 2004;292:224-236.
30. Mezinskis J, Karr C, Kropp F, et al. The "good subject effect": invalid denial of drug use increases as a function of time in the study. Presented at: The Meeting of The College on Problems on Drug Dependence, 2001.
31. Rosenthal R, Rosnow RL. Subject-experimenter artifacts and their control. In: Essentials of Behavioral Research: Methods and Data Analysis. 2nd ed. McGraw-Hill Inc., NY. 1991:110-134.
32. Bednar RL, Kaul TJ. Experiential group research: can the canon fire? In: Handbook of Psychotherapy and Behavior Change. New York: John Wiley and Sons; 1994:631-663.
33. Toro PA, Rappaport J, Seidman E. Social climate comparison of mutual help and psychotherapy groups. J Consult Clinical Psychol. 1987;55: 430-431.